Cerro Pacific Wealth Advisors LLC Purchases 828 Shares of Novo Nordisk A/S (NYSE:NVO)

Cerro Pacific Wealth Advisors LLC raised its position in Novo Nordisk A/S (NYSE:NVO) by 33.5% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,301 shares of the company’s stock after purchasing an additional 828 shares during the period. Cerro Pacific Wealth Advisors LLC’s holdings in Novo Nordisk A/S were worth $284,000 as of its most recent filing with the SEC.

Several other hedge funds also recently bought and sold shares of NVO. Strategic Investment Solutions Inc. IL bought a new stake in shares of Novo Nordisk A/S in the 2nd quarter valued at $25,000. Daiwa Securities Group Inc. bought a new position in shares of Novo Nordisk A/S during the 3rd quarter valued at about $28,000. Capital Performance Advisors LLP acquired a new position in shares of Novo Nordisk A/S in the 3rd quarter valued at approximately $42,000. Albion Financial Group UT increased its stake in Novo Nordisk A/S by 121.4% during the 4th quarter. Albion Financial Group UT now owns 507 shares of the company’s stock worth $44,000 after purchasing an additional 278 shares in the last quarter. Finally, Carolina Wealth Advisors LLC acquired a new stake in Novo Nordisk A/S during the 3rd quarter worth approximately $48,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

NVO has been the subject of several research reports. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. BMO Capital Markets dropped their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research note on Monday, December 23rd. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Trading Up 1.0 %

Shares of Novo Nordisk A/S stock opened at $81.36 on Friday. Novo Nordisk A/S has a 12-month low of $78.17 and a 12-month high of $148.15. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The business’s 50 day moving average is $96.10 and its 200-day moving average is $115.79. The stock has a market cap of $365.09 billion, a P/E ratio of 26.33, a P/E/G ratio of 0.90 and a beta of 0.45.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.